Skip to main content
Equibles

Sands Capital Alternatives, LLC

Position in CADL — Candel Therapeutics, Inc.

CIK 1846444 ARLINGTON, VA
Back to CADL Full portfolio

Position in CADL

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$4,180,121
+$2,191,520 QoQ
Shares Held
405,837
0.0% QoQ
Ownership
0.530%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#16
of 138 holders
Holding Since
Sep 2021
20 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in CADL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Sands Capital Alternatives, LLC holds $126,924,003 across 8 Biotechnology names. CADL ranks #7 (3.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 SGP
SpyGlass Pharma, Inc.
 2,500,012 $55,650,267
2 IKT
Inhibikase Therapeutics, Inc.
 13,018,965 $26,428,498
3 ODTX
Odyssey Therapeutics, Inc.
 875,000 $16,371,250
4 ABOS
Acumen Pharmaceuticals, Inc.
 3,720,105 $9,932,680
5 TARS
Tarsus Pharmaceuticals, Inc.
 85,000 $5,349,900
6 TSHA
Taysha Gene Therapies, Inc.
 724,873 $4,936,385
7 CADL
Candel Therapeutics, Inc.
This page 		405,837 $4,180,121
8 ACRV
Acrivon Therapeutics, Inc.
 2,289,271 $4,074,902

All Filings in CADL

Export CSV
20 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,180,121 405,837
2026-03-31 $1,988,601 405,837
2025-12-31 $2,292,979 405,837
2025-09-30 $2,069,768 405,837
2025-06-30 $2,053,535 405,837
2025-03-31 $2,292,979 405,837
2024-12-31 $3,522,665 405,837
2024-09-30 $2,812,450 405,837
2024-06-30 $2,516,189 405,837
2024-03-31 $1,282,544 811,737
2023-12-31 $1,193,253 811,737
2023-09-30 $746,798 811,737
2023-06-30 $1,022,788 811,737
2023-03-31 $1,095,844 811,737
2022-12-31 $1,453,009 811,737
2022-09-30 $2,548,854 811,737
2022-06-30 $2,630,027 811,737
2022-03-31 $4,131,741 811,737
2021-12-31 $6,347,783 811,737
2021-09-30 $8,799,229 811,737